Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide in Barth syndrome
NCT03098797Phase 3Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Jul 2017
- Primary completion
- Oct 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elamipretide in Barth syndrome (BTHS), sponsored by Stealth BioTherapeutics. Started Jul 2017; status: completed.
02
Drugs
elamipretide
03
Conditions
Barth syndrome (BTHS)
Beyond the preview
Go deeper on NCT03098797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03098797.